Vancouver, B.C. and Boston, MA, November10, 2016 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today that Dr. Roger J. Buckley, has joined Imagin’s Scientific Board of Advisors.
Dr. Buckley is the Division Head of Urology at North York General Hospital in Toronto, and is considered a top urologist in Canada. He received his M.D. from the University of Toronto medical school where he also completed his urological Residency and Fellowship. Dr. Buckley has worked full-time at North York General Hospital (NYGH) since 1985 where he has been Chief of Urology since 2002. North York General is a large community hospital in Toronto with teaching affiliations to the University of Toronto. He has been vice president and president of the Medical Staff Association at NYGH and a member of the Board of Governors.
Dr. Buckley conceptualized and opened the Gale and Graham Wright Prostate Center at NYGH in 2007, the first prostate centre in the province to offer timely diagnosis, information, expertise and resources for prostate cancer in a community hospital setting. He also developed and has chaired the International Bladder Cancer Group (IBCG) from 2006-2016, a consortium of American, Canadian and European Union countries whose mission is to improve the diagnosis, prevention, and treatment of bladder cancer through the application of biologic markers. He is currently vice president of the IBCG, and as a member has co-authored numerous peer-reviewed articles on bladder cancer. He has an ongoing interest in bladder cancer and prostate research and education.
“We are excited to have Dr. Buckley join our Scientific Advisory Board. His current interests and activities within the area of bladder cancer and its treatment complement the expertise of our other Board members. His involvement and relationships in the EU will be an asset to Imagin as we move forward,” said Jim Hutchens, Imagin President and CEO.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imagindev.wpengine.com.
ON BEHALF OF THE BOARD:
President & CEO
For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292
Email: [email protected]
Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.